CN Patent

CN114423786A — 高亲和力的、配体阻断性、人源化的抗T细胞免疫球蛋白结构域和粘蛋白结构域3（TIM-3）IgG4抗体用于治疗骨髓纤维化的用途

Assigned to Novartis AG · Expires 2022-04-29 · 4y expired

What this patent protects

本发明涉及抗TIM‑3抗体分子在治疗骨髓纤维化(MF)中的用途。本发明还涉及药物组合，所述药物组合包含a)抗TIM‑3抗体分子，和b)至少一种另外的治疗剂，优选为鲁索替尼或其药学上可接受的盐。

USPTO Abstract

本发明涉及抗TIM‑3抗体分子在治疗骨髓纤维化(MF)中的用途。本发明还涉及药物组合，所述药物组合包含a)抗TIM‑3抗体分子，和b)至少一种另外的治疗剂，优选为鲁索替尼或其药学上可接受的盐。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN114423786A
Jurisdiction: CN
Classification: —
Expires: 2022-04-29
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.